These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 465283)

  • 1. Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients.
    Finch RE; Bending MR; Lant AF
    Br J Clin Pharmacol; 1979 Jun; 7(6):613-7. PubMed ID: 465283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oral and intravenous fluorouracil in humans.
    Phillips TA; Howell A; Grieve RJ; Welling PG
    J Pharm Sci; 1980 Dec; 69(12):1428-31. PubMed ID: 7463330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered plasma kinetics of 5-FU at high dosage in rat and man.
    Schwartz PM; Turek PJ; Hyde CM; Cadman EC; Handschumacher RE
    Cancer Treat Rep; 1985 Jan; 69(1):133-6. PubMed ID: 3967255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography.
    Finj C; Sadée W
    Cancer Chemother Rep; 1975; 59(2 Pt 1):279-86. PubMed ID: 1097091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity.
    Codacci-Pisanelli G; Pinedo HM; Lankelma J; Van Groeningen CJ; Van Kuilenburg AB; Van Gennip AH; Peters GJ
    J Chemother; 2005 Jun; 17(3):315-20. PubMed ID: 16038526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of 5-fluorouracil after intravenous bolus doses of a commercial formulation to cancer patients.
    Sitar DS; Shaw DH; Thirlwell MP; Ruedy JR
    Cancer Res; 1977 Nov; 37(11):3981-4. PubMed ID: 908036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration.
    Chirstophidis N; Vajda FJ; Lucas I; Drummer O; Moon WJ; Louis WJ
    Clin Pharmacokinet; 1978; 3(4):330-6. PubMed ID: 678346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients.
    Casale F; Canaparo R; Serpe L; Muntoni E; Pepa CD; Costa M; Mairone L; Zara GP; Fornari G; Eandi M
    Pharmacol Res; 2004 Aug; 50(2):173-9. PubMed ID: 15177306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.
    Säwe J
    Clin Pharmacokinet; 1986; 11(2):87-106. PubMed ID: 3514045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes.
    Collins JM; Dedrick RL; King FG; Speyer JL; Myers CE
    Clin Pharmacol Ther; 1980 Aug; 28(2):235-46. PubMed ID: 7398191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer.
    Reid JM; Kovach JS; O'Connell MJ; Bagniewski PG; Moertel CG
    Cancer Chemother Pharmacol; 1998; 41(6):477-84. PubMed ID: 9554592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893).
    Cohen JL; Irwin LE; Marshall GJ; Darvey H; Bateman JR
    Cancer Chemother Rep; 1974; 58(5 Pt 1):723-31. PubMed ID: 4609602
    [No Abstract]   [Full Text] [Related]  

  • 15. Determination of 5-fluorouracil in plasma by GC/MS using an internal standard. Applications to pharmacokinetics.
    Cano JP; Rigault JP; Aubert C; Carcassonne Y; Seitz JF
    Bull Cancer; 1979; 66(1):67-74. PubMed ID: 420949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of fluorouracil in humans.
    MacMillan WE; Wolberg WH; Welling PG
    Cancer Res; 1978 Oct; 38(10):3479-82. PubMed ID: 688233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral melphalan kinetics.
    Alberts DS; Chang SY; Chen HS; Evans TL; Moon TE
    Clin Pharmacol Ther; 1979 Dec; 26(6):737-45. PubMed ID: 498715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion.
    Fraile RJ; Baker LH; Buroker TR; Horwitz J; Vaitkevicius VK
    Cancer Res; 1980 Jul; 40(7):2223-8. PubMed ID: 7388790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group.
    Patel R; Newman EM; Villacorte DG; Sato JK; Reaman GH; Finklestein JZ; Krailo MD; Hammond GD; Holcenberg JS
    Cancer Res; 1991 Sep; 51(18):4871-5. PubMed ID: 1893377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.